Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
Jonah Feldman
Advertisement
Articles by Jonah Feldman
A prespecified interim analysis from the phase 3 TRANSFORM study showed an event-free survival benefit with the second-line therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – December 3, 2025
2
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
3
Lessons Learned From the Past 25 Years of Cell and Gene Therapy Research
4
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
5
